Nonprofit · EIN 13-4137654
HEREDITARY NEUROPATHY FOUNDATION INC
Tax-exempt · NEW YORK, NY 10128
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| June 30, 2025 | 990 | $545,418 | $894,903 | -$349,485 | $1,016,066 | $6,182 | $1,009,884 |
| June 30, 2024 | 990 | $655,296 | $730,003 | -$74,707 | $1,503,541 | $62,343 | $1,441,198 |
| June 30, 2023 | 990 | $543,625 | $671,491 | -$127,866 | $1,515,448 | $12,282 | $1,503,166 |
Financial details: 990 for the year ended June 30, 2025
Revenue
- Contributions, gifts and grants
- $582,345
- Program service revenue
- $0
- Investment income
- $5,908
- Net income from fundraising events
- -$43,089
- Other revenue
- -$42,835
Expenses
- Grants and similar amounts paid
- $319,283
- Compensation of officers, directors and key employees
- $61,154
- Other salaries and wages
- $73,846
- Salaries, compensation and benefits (total)
- $198,415
- Professional fundraising fees
- $0
- Accounting fees
- $21,665
- Occupancy
- $504
- Depreciation
- $346
- Program services (functional)
- $805,802
- Management and general (functional)
- $55,157
- Fundraising (functional)
- $33,944
Balance sheet and other
- Total assets, start of year
- $1,503,541
- Total assets, end of year
- $1,016,066
- Total liabilities, end of year
- $6,182
- Net assets, end of year
- $1,009,884
- Land, buildings and equipment
- $921
- Publicly traded securities
- $144,476
- Net assets without donor restrictions
- $92,323
- Net assets with donor restrictions
- $917,561
- Gross receipts
- $588,507
- Employees
- 2
- Volunteers
- 9
- Year formed
- 2001
- State of legal domicile
- NY
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended June 30, 2025, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| COURTNEY HOLLETT | EXECUTIVE DIRECTOR Officer | 40 | $75,000 | $0 |
| ALLISON MOORE | FOUNDER AND CHIEF EXECUTIV Trustee or director, Officer | 50 | $0 | $52,675 |
| KARA SPRAGUE | TREASURER Trustee or director, Officer | 5 | $0 | $0 |
| MATTHEW DOWNING | CHAIRMAN Trustee or director, Officer | 5 | $0 | $0 |
| KERIN REILLY | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| GRETCHEN CAPPIELLO | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| BROOKE WARREN | SECRETARY Trustee or director, Officer | 5 | $0 | $0 |
| ROBERT KAUFFMAN | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| DOMINIC HADEED | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| SITAL BHAVSAR | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| NATALIA SALEJKO | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| DENNIS SULLIVAN | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| POYA GHASRI | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
990 for the year ended June 30, 2024: 15 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| COURTNEY HOLLETT | EXECUTIVE DIRECTOR Officer | 40 | $73,846 | $0 |
| ALLISON MOORE | FOUNDER AND CHIEF EXECUTIV Trustee or director, Officer | 50 | $0 | $49,449 |
| KARA SPRAGUE | TREASURER Trustee or director, Officer | 5 | $0 | $0 |
| MATTHEW DOWNING | CHAIRMAN Trustee or director, Officer | 5 | $0 | $0 |
| KERIN REILLY | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| GRETCHEN CAPPIELLO | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| DEBORAH NEWCOMB | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| BROOKE WARREN | SECRETARY Trustee or director, Officer | 5 | $0 | $0 |
| ROBERT KAUFFMAN | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| DOMINIC HADEED | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| SITAL BHAVSAR | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| NATALIA SALEJKO | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| JOY ANDAL KAYE | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| DEBI HOUILARES | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| POYA GHASRI | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
990 for the year ended June 30, 2023: 15 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| COURTNEY HOLLETT | EXECUTIVE DIRECTOR Officer | 40 | $60,000 | $0 |
| ALLISON MOORE | FOUNDER AND CHIEF EXECUTIV Trustee or director, Officer | 50 | $0 | $46,845 |
| KARA SPRAGUE | TREASURER Trustee or director, Officer | 5 | $0 | $0 |
| MATTHEW DOWNING | CHAIRMAN Trustee or director, Officer | 5 | $0 | $0 |
| KERIN REILLY | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| GRETCHEN CAPPIELLO | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| DEBORAH NEWCOMB | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| BROOKE WARREN | SECRETARY Trustee or director, Officer | 5 | $0 | $0 |
| ROBERT KAUFFMAN | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| DOMINIC HADEED | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| SITAL BHAVSAR | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| NATALIA SALEJKO | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| JOY ANDAL KAYE | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| DEBI HOUILARES | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
| POYA GHASRI | BOARD MEMBER Trustee or director | 5 | $0 | $0 |
Address and contacts
- Address (IRS master file)
- 1641 3RD AVE, NEW YORK, NY 10128-3623
- In care of
- % ALLISON T MOORE
- Principal officer (990 for 2024)
- ALLISON MOORE, 1641 3RD AVE 28K, NEW YORK, NY 10128
- Signed the 990
- ALLISON MOORE, CEO/FOUNDER
- Phone
- (212) 722-8396
- Website
- WWW.HNF-CURE.ORG
- Return prepared by
- TEAL BECKER & CHIARAMONTE CPAS PC
Mission
HNF, INC., A NON-PROFIT DEDICATED TO SUPPORTING PROJECTS THROUGH THE THERAPEUTIC RESEARCH IN ACCELERATED DISCOVERY (TRIAD)PROGRAM, A COLLABORATIVE EFFORT WITH ACADEMIA, GOVERNMENT AND INDUSTRY, TO DEVELOP TREATMENTS FOR CMT. CURRENTLY TRIAD INVOLVES MANY GROUPS THAT SPAN THE DRUG DISCOVERY, DRUG DEVELOPMENT, AND DIAGNOSTICS CONTINUUM. EDUCATION AND SUPPORT OF THE CMT COMMUNITY TO IMPROVE QUALITY OF LIFE IS ALSO A KEY COMPONENT OF HNF'S MISSION.
Program accomplishments
- RESEARCH PROGRAMS ARE AS FOLLOWS: THERAPEUTIC RESEARCH IN ACCELERATED DISCOVERY (TRIAD) CONTINUES TO SERVE AS HNF'S PRIMARY TRANSLATIONAL RESEARCH ACCELERATOR, SUPPORTING THE DEVELOPMENT OF ESSENTIAL RESEARCH TOOLS (INCLUDING IPSCS AND ANIMAL MODELS), THERAPEUTIC CANDIDATES, DRUG SCREENING INITIATIVES, GENE THERAPY PROGRAMS, AND DIGITAL HEALTH TECHNOLOGY INNOVATIONS. THE PROGRAM MAINTAINS STRONG PARTNERSHIPS WITH ACADEMIC INSTITUTIONS, REGULATORY AGENCIES, AND INDUSTRY COLLABORATORS AND ADVANCES KEY SCIENTIFIC INITIATIVES IN BIOMARKER DEVELOPMENT, CLINICAL ENDPOINT REFINEMENT, AND THERAPY TRANSLATION. TRIAD ALSO LEADS THE ANNUAL CMT CLINICAL TRIAL READINESS SUMMIT, WHICH BRINGS TOGETHER GLOBAL EXPERTS TO ALIGN ON REGULATORY EXPECTATIONS, OPTIMIZE TRIAL DESIGN, AND ACCELERATE THERAPY DEVELOPMENT. THE GLOBAL REGISTRY FOR INHERITED NEUROPATHIES (GRIN) CONTINUES TO GROW AS AN INTERNATIONAL CMT PATIENT REGISTRY, CAPTURING NATURAL HISTORY DATA AND PROVIDING COMPREHENSIVE PATIENT-REPORTED, CLINICAL, DIGITAL, AND GENETIC DATASETS. GRIN PLAYS A CRITICAL ROLE IN CLINICAL TRIAL READINESS, SUPPORTING FEASIBILITY ASSESSMENTS, ENDPOINT DEVELOPMENT, AND PATIENT RECRUITMENT FOR THERAPEUTIC DEVELOPMENT PROGRAMS. GRIN INSIGHTS AND DATA INFRASTRUCTURE INFORM KEY SESSIONS AND WORKING GROUPS AT THE CMT CLINICAL TRIAL READINESS SUMMIT, HELPING RESEARCHERS AND INDUSTRY PARTNERS ADDRESS UNMET NEEDS AND STRENGTHEN FUTURE TRIAL STRATEGIES. THE CMT BIOBANK CONTINUES TO EXPAND ITS PATIENT SAMPLE COLLECTION, INCLUDING BLOOD, SALIVA, TISSUE, SKIN FIBROBLASTS, IPSCS, AND OTHER BIOSPECIMENS DONATED BY INDIVIDUALS WITH CMT. THESE SAMPLES ARE PROCESSED AND STORED UNDER STRICT QUALITY-CONTROLLED PROTOCOLS AND REMAIN SECURELY LINKED TO GRIN CLINICAL, DIGITAL, AND GENETIC DATA. THIS INTEGRATED RESOURCE SUPPORTS PRE-COMPETITIVE BIOMARKER DISCOVERY, MOLECULAR RESEARCH, AND DIGITAL BIOMARKER VALIDATION, ENABLING RESEARCHERS AND INDUSTRY PARTNERS TO ACCELERATE THERAPEUTIC DEVELOPMENT. FINDINGS AND COLLABORATIVE OPPORTUNITIES FROM THE BIOBANK ARE REGULARLY HIGHLIGHTED AT THE CMT CLINICAL TRIAL READINESS SUMMIT, WHERE CROSS-SECTOR PARTNERS ALIGN ON BIOMARKER PRIORITIES AND STRATEGIES TO ADVANCE FUTURE TREATMENTS.Expenses $805,802 · grants $319,283
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in June, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | June 30, 2026 | November 16, 2026 | Not due yet |
| 2024 | June 30, 2025 | November 17, 2025 | 990 on file |
| 2023 | June 30, 2024 | November 15, 2024 | 990 on file |
IRS record
- EIN
- 13-4137654
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (170(b)(1)(A)(vi))
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 2001
- Accounting year ends
- June
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Medical research (H129)
- Assets (IRS master file)
- $1,016,066
- Income (IRS master file)
- $588,507
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | June 2025 | $545,418 | $894,903 | $1,016,066 | IRS |
| 990 | June 2024 | $655,296 | $730,003 | $1,503,541 | IRS |
| 990 | June 2023 | $543,625 | $671,491 | $1,515,448 | XML |
| 990 | June 2022 | $1,259,879 | $759,374 | $1,627,053 | IRS |
| 990 | June 2021 | – | – | – | IRS |
| 990 | June 2020 | – | – | – | IRS |
| 990 | June 2019 | – | – | – | IRS |
| 990 | June 2018 | – | – | – | IRS |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 13-4137654).
Questions about HEREDITARY NEUROPATHY FOUNDATION INC
- What is the EIN of HEREDITARY NEUROPATHY FOUNDATION INC?
- The employer identification number (EIN) of HEREDITARY NEUROPATHY FOUNDATION INC is 13-4137654.
- Is HEREDITARY NEUROPATHY FOUNDATION INC tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2001.
- Are donations to HEREDITARY NEUROPATHY FOUNDATION INC tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does HEREDITARY NEUROPATHY FOUNDATION INC file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of HEREDITARY NEUROPATHY FOUNDATION INC due?
- The return for tax year 2025 (the year ending June 30, 2026) is due November 16, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did HEREDITARY NEUROPATHY FOUNDATION INC last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended June 2025.
- Who is the principal officer of HEREDITARY NEUROPATHY FOUNDATION INC?
- The 990 for the year ended June 30, 2025 names ALLISON MOORE.
- Who are the officers and directors of HEREDITARY NEUROPATHY FOUNDATION INC?
- The 990 for the year ended June 30, 2025 lists 13 people; 1 received compensation from the organization, the highest $75,000 (COURTNEY HOLLETT, EXECUTIVE DIRECTOR).
- How much revenue does HEREDITARY NEUROPATHY FOUNDATION INC have?
- On its 990 for the year ended June 30, 2025 it reported revenue of $545,418, expenses of $894,903 and total assets of $1,016,066 at year end.
Other nonprofits in NEW YORK
- MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH EIN 13-4141945 · last filed 990 for 2025
- PUBLIC HEALTH SOLUTIONS EIN 13-5669201 · last filed 990 for 2025
- PARKINSONS FOUNDATION INC EIN 13-1866796 · last filed 990 for 2025
- LICR FUND INC EIN 13-3573053 · last filed 990 for 2024
- CARDIOVASCULAR RESEARCH FOUNDATION EIN 52-1752653 · last filed 990 for 2024
- GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC EIN 13-4128413 · last filed 990 for 2024
- INTERNATIONAL BRAIN RESEARCH ORGANIZATION EIN 88-4372025 · last filed 990 for 2024
- CANCER RESEARCH INSTITUTE INC EIN 13-1837442 · last filed 990 for 2025